Watch experts Drs. Raj Chovatiya and Matt Zirwas at an educational symposium on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.

This educational video series provides expert commentary on the results and implications of Level Up, the first head-to-head trial in atopic dermatitis assessing upadacitinib (Rinvoq, AbbVie) at a starting dose of 15mg daily vs. dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals) at its labeled dose.